SCHEMBL353786

SCHEMBL353786

Cc1ccc(S(N)(=O)=O)cc1C(=O)N(C)Cc1csc(NC(=O)NCc2ccc(Cl)s2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.37
HCRTR1 O43613 1/20 0.36
MEN1 O00255 3/20 0.35
HSD17B10 Q99714 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CA2 P00918 2/20 0.34
LMNA P02545 2/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA9 Q16790 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
GAA P10253 3/20 0.33
KDM4E B2RXH2 2/20 0.33
XBP1 P17861 1/20 0.33
ALOX12 P18054 1/20 0.33
BLM P54132 1/20 0.33
ROCK1 Q13464 1/20 0.33
MAPT P10636 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353272 0.87 KMT2A (0.37) KMT2AHCRTR1MEN1HSD17B10ALDH1A1
SCHEMBL353144 0.83 F10 (0.33) KMT2AMEN1HSD17B10ALDH1A1LMNA
SCHEMBL353558 0.83 ROCK2 (0.48) KMT2AHCRTR1ROCK1
SCHEMBL355250 0.82 KMT2A (0.38) KMT2AMEN1ALDH1A1LMNANPC1
SCHEMBL352881 0.79 KMT2A (0.40) KMT2AMEN1HSD17B10ALDH1A1LMNA
SCHEMBL354091 0.79 MEN1 (0.35) KMT2AMEN1ALDH1A1LMNANPC1
SCHEMBL353171 0.78 ALDH1A1 (0.38) KMT2AMEN1ALDH1A1LMNAGAA
SCHEMBL354863 0.77 KMT2A (0.39) KMT2AMEN1HSD17B10ALDH1A1LMNA
SCHEMBL352359 0.77 LMNA (0.41) KMT2AMEN1HSD17B10ALDH1A1LMNA
SCHEMBL353762 0.76 NPC1 (0.37) KMT2AMEN1ALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA KMT2A 1210/4885HCRTR1 4112/4885MEN1 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.